Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

PR Newswire March 19, 2015

Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights

PR Newswire March 16, 2015

Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015

PR Newswire March 11, 2015

Synthetic Biologics to Report Year End 2014 Financial Results

PR Newswire March 9, 2015

Synthetic Biologics to Present at the 27th Annual ROTH Conference

PR Newswire March 3, 2015

Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015

PR Newswire March 2, 2015

Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week® 2015

PR Newswire February 17, 2015

Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

PR Newswire February 10, 2015

Synthetic Biologics to Present at the 2015 BIO CEO & Investor Conference

PR Newswire February 3, 2015

Synthetic Biologics to Present at the Biotech Showcase(TM) 2015 Conference

PR Newswire January 7, 2015

Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

PR Newswire December 30, 2014

Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection

PR Newswire December 22, 2014

Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

PR Newswire December 2, 2014

Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection

PR Newswire November 24, 2014

Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights

PR Newswire November 14, 2014

Synthetic Biologics to Report Third Quarter 2014 Financial Results

PR Newswire November 6, 2014

Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program

PR Newswire October 22, 2014

Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board

PR Newswire October 15, 2014

Synthetic Biologics to Raise $20.7 Million in Registered Direct Offering

PR Newswire October 10, 2014

Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day

PR Newswire September 16, 2014